Smoking Status Must Be Recorded in Cancer Trials, Experts Urge

New Delhi, August 18:
A global coalition of cancer researchers, led by scientists from AIIMS Delhi, McMaster University (Canada), and the International Agency for Research on Cancer (France), has called for mandatory recording of patients’ smoking status in cancer clinical trials. Their commentary, published in The Lancet Oncology, underscores the urgent need to integrate detailed tobacco-use assessments and cessation support into oncology research, warning that continued tobacco consumption can severely diminish treatment efficacy and patient survival.

Impact of Smoking on Cancer Outcomes

The experts highlight that persistently high tobacco use not only worsens cancer outcomes but may compromise the results of new therapies. Evidence, including findings from the 2014 US Surgeon General’s landmark report, establishes a clear causal link between cigarette smoking and poor cancer-related outcomes—ranging from heightened mortality to complications during treatment. Mechanisms cited include tumor hypoxia, altered drug metabolism, and adverse immune changes driven by nicotine and other compounds.

Gaps in Data Collection and Clinical Practice

Despite mounting evidence and recommendations from authorities such as the US Surgeon General and leading international agencies, robust tobacco-use assessments remain rare in most cancer trials. The group notes that inconsistent data collection—aggravated by the absence of standardised tools, underdeveloped electronic health record systems, and limited resources in trial settings—poses a major barrier to reliable outcomes. In lower and middle-income countries, where 80% of the world’s tobacco users reside, this issue is particularly acute.

Survival Advantage of Quitting

Compelling meta-analyses and recent studies find that quitting smoking after a cancer diagnosis significantly prolongs survival, with the benefit greatest for those who stop early. In some cancers, the survival improvement linked to quitting outstrips that offered by the cancer therapy itself.

Call to Action for Cancer Trial Design

The experts argue that recording smoking status can help clinicians tailor therapy, as in the example of erlotinib, where dosages must be adjusted for current smokers. Omission of tobacco-use data, they caution, may also risk confounding trial results due to group imbalances.

Recent international initiatives—such as the IASLC’s 2023 position statement and efforts by cancer centers across Canada, Australia, and the US—reflect growing consensus for standardized tobacco-control practices within cancer care and research. The commentary strongly recommends making smoking status capture “an essential core element of cancer research, no longer considered optional.”

Disclaimer

This article is intended for general informational purposes and does not constitute medical advice. Patients should consult healthcare professionals regarding smoking cessation and cancer therapy. The views expressed are based on published research and expert opinions.

Reference: “Smoking status must be recorded in cancer trials: Researchers.” The Tribune.